Dr James Lee |
The group was founded by Suzanne Neate, following the loss of her mother to metastatic medullary thyroid cancer. Thyroid cancer is now the 7th most commonly diagnosed cancer in women overall, and is on the rise.
There are a number of challenges to accurately diagnosing
and profiling thyroid cancers, which makes it difficult to select the most
appropriate treatment. Molecular profiling of thyroid FNA (needle biopsy)
samples is believed to hold some promise to reduce, if not eliminate,
preoperative uncertainty. This is only available in the USA, and published
evidence to date casts doubt on the current utility of the tests in their
current status.
Dr Lee believes that with further research here in Victoria,
the potential of FNA molecular testing will be realised. He says,
"There is no doubt that precision medicine with
molecular techniques is the next frontier. Whether it is to inform diagnosis,
prognosis or likely response to treatment, the integration of pre-operative
molecular testing should give treating doctors more confidence that they are
providing the best treatment for patients with rare cancers such as thyroid
cancer."
Dr Lee is also incredibly grateful for the vote of
confidence The Aftershock has shown by investing in his research.
"The support of philanthropic foundations such as The
Aftershock is vital to research and development of new techniques here in
Victoria. As a rare cancer, research in thyroid cancer are ideally conducted in
multicenter studies, and non-institutional seed funding affords the researcher
freedom to be collaborative."
Only one year into their existence, The Aftershock is
already making a significant contribution to the medical research of rare
cancers here in Victoria. Further funds have been pledged for both thyroid and
brain cancers in the coming years.
For more information on The Aftershock, go to www.theaftershock.org
No comments:
Post a Comment
Thankyou for your comment. We moderate all messages and may take a little time to review your comment. Please email inquiries to ccs.comms@monash.edu.